Zoetis Inc. Class A ($ZTS) Stock Forecast: Down 5.3% Today

What is Zoetis Inc. Class A?

Zoetis Inc (ZTS) is a company specializing in animal health products, offering anti-infectives, vaccines, parasiticides, and diagnostics for both production and companion animals. Recently, the company has faced challenges in its U.S. companion animal business, leading to a bearish movement in its stock price.

Why is Zoetis Inc. Class A going down?

ZTS stock is down 5.3% on May 11, 2026 19:16

• Zoetis Inc (ZTS) experienced a strong bearish movement following the company's decision to lower its full-year guidance due to challenges in its U.S. companion animal business.
• Increased price sensitivity, fewer vet visits, and generic competition in the U.S. pet segment have contributed to the decline in Zoetis' stock price.
• The company is implementing strategic measures focusing on integrated solutions, cost controls, and operational efficiency to address the challenges in its pet segment while leveraging its more resilient livestock and international businesses.
• Despite the bearish movement, Zoetis Inc's long-term prospects in the animal health industry remain solid, with potential for recovery as the company executes its strategic reset.

ZTS Price Chart

ZTS Technical Analysis

ZTS News

Ies Holdings stock hits all-time high at 690.31 USD

IES Holdings Inc. (IESC) reached an all-time high of $690.31, reflecting a 171% increase over the past year. Despite this, InvestingPro analysis indicates the stock is currently overvalued. The company recently reported strong Q2 fiscal 2026 results driven by non-residential market expansion, leading Freedom Broker to downgrade its rating to "hold" while raising the price target to $700.

https://www.investing.com/news/company-news/ies-holdings-stock-hits-alltime-high-at-69031-usd-93CH-4677246

Monday.com Releases Q1 2026 Financial Results

Monday.com Ltd. announced strong first-quarter 2026 results, surpassing Wall Street expectations with non-GAAP earnings of $1.15 per share and revenues of $351.3 million, a 24% increase from the previous year. The company's performance was driven by accelerated demand for its workflow management platform, deepening customer relationships, and expansion into enterprise markets, maintaining a net dollar retention rate of +110.0%. This robust growth and profitability have kept investor interest high, with analysts largely bullish on the stock.

https://news.alphastreet.com/monday-com-releases-q1-2026-financial-results/

Zoetis Inc (CHIX:ZOEd) Stock Price, Trades & News

This article provides a detailed stock summary for Zoetis Inc (CHIX:ZOEd), including its current stock price, market capitalization, financial ratios, and key dates such as earnings calls and general meetings. It also highlights the company's business description, financial strength, growth metrics, profitability, and lists various warning signs detected by GuruFocus. The company, formerly Pfizer's animal health unit, sells anti-infectives, vaccines, parasiticides, and diagnostics for both production and companion animals.

https://www.gurufocus.com/stock/CHIX:ZOED/summary

Zoetis Inc (CHIX:ZOEd) Stock Price, Trades & News

This page provides comprehensive financial data, news, and analysis for Zoetis Inc (CHIX:ZOEd), a company specializing in animal health products. It details the stock's performance metrics, financial strength, growth rates, profitability, and valuation, alongside business descriptions, executive information, and upcoming investor events. The article notes a medium warning sign detected by GuruFocus for ZOEd.

https://www.gurufocus.com/stock/CHIX:ZOEd/summary

Zoetis Resets Outlook As U.S. Pet Weakness Pressures Valuation And Growth

Zoetis (NYSE: ZTS) has lowered its full-year guidance due to a significant decline in its U.S. companion animal business, attributed to increased price sensitivity, fewer vet visits, and generic competition. The company is implementing a broad reset focusing on integrated solutions, cost controls, and operational efficiency, following a substantial drop in its share price. This strategic shift aims to address the challenges in its pet segment while leveraging its more resilient livestock and international businesses.

https://www.sahmcapital.com/news/content/zoetis-resets-outlook-as-us-pet-weakness-pressures-valuation-and-growth-2026-05-08

Trending Today

Perrigo Company plc ($PRGO) Stock Forecast: Down 5.0% Today

CF Industries Holdings Inc. ($CF) Stock Forecast: Up 5.6% Today

Airbnb Inc. ($ABNB) Stock Forecast: Down 5.1% Today

AMC Entertainment Holdings Inc. Class A ($AMC) Stock Forecast: Down 5.2% Today

Zebra Technologies Corporation ($ZBRA) Stock Forecast: Down 5.1% Today

Trimble Inc. ($TRMB) Stock Forecast: Down 5.1% Today

Booking Holdings Inc. ($BKNG) Stock Forecast: Down 5.0% Today

Zoetis Inc. Class A ($ZTS) Stock Forecast: Down 5.3% Today

Amplitude Inc. ($AMPL) Stock Forecast: Down 5.1% Today

Excelerate Energy ($EE) Stock Forecast: Up 5.1% Today

Zoetis Inc. Class A Price History

08.04.2026 - ZTS Stock was down 7.6%

• Today, Zoetis (ZTS) experienced a significant bearish movement.
• Despite a positive outlook for a competitor in the animal health industry, Zoetis faced a bearish market movement.
• The overall U.S. stock market indexes closed down, with a stock noted as the stock that fell the furthest, indicating a broader negative sentiment in the market.
• Some companies saw rallies, while others experienced declines, showcasing mixed movements in the market that may have impacted Zoetis' stock price.
• Analysts estimating a decline in earnings and revenues for another company could have influenced overall sector sentiment, potentially affecting Zoetis' stock performance negatively.

08.04.2026 - ZTS Stock was down 6.9%

• Zoetis (ZTS) experienced a strong bearish movement today amidst a generally negative day for U.S. stock indexes, with the Dow Jones, S&P 500, and NASDAQ all closing in the red.
• The bearish trend in Zoetis' stock could be attributed to the broader market decline, as well as negative sentiment towards the healthcare sector.
• The ripple effect of another pharmaceutical company facing challenges in earnings and revenues might have impacted investor confidence in pharmaceutical companies, indirectly affecting Zoetis.
• Additionally, the focus on stocks hitting 52-week lows, including Zoetis, could have added to the selling pressure on the company's shares as investors reevaluated their positions in underperforming stocks.

13.01.2026 - ZTS Stock was up 6.6%

• Zoetis Inc. (ZTS) experienced a strong bullish movement today following its impressive Q4 earnings and optimistic 2026 guidance.
• The company reported Q4 revenue and adjusted EPS that exceeded estimates, showcasing strong financial performance.
• The positive market reaction can be attributed to Zoetis' solid financial results and optimistic outlook for future revenue and earnings growth, indicating investor confidence in the company's strategic direction and market positioning.
• This bullish momentum for Zoetis might have been further fueled by the overall positive sentiment in the animal health industry, as evidenced by institutional investments in related companies like Elanco Animal Health.

12.01.2026 - ZTS Stock was down 6.7%

• Zoetis Inc. (ZTS) achieved strong Q4 revenue of $2.39 billion, exceeding expectations, and offered optimistic 2026 guidance.
• Despite the positive financial results, the downward trend in ZTS stock may be linked to investors taking profits following a period of growth.
• The anticipated growth of the animal vaccine market suggests a favorable future for Zoetis, although market sentiment and broader economic factors could have impacted the stock's decline.
• Investor apprehension may stem from market uncertainties and potential competition from other industry players like Merck and Boehringer Ingelheim within the animal vaccine sector.

12.01.2026 - ZTS Stock was down 1.0%

• Zoetis Inc. (ZTS) posted impressive Q4 revenue of $2.39 billion, surpassing expectations. However, despite this positive performance, the stock witnessed a bearish trend.
• The State of Michigan Retirement System's investment in Elanco Animal Health (ELAN) and favorable views on Elanco by analysts could have diverted investor focus from Zoetis, impacting its stock trajectory.
• Anticipated growth in the animal vaccine market overall and heightened competition from industry players such as Merck and Boehringer Ingelheim may have also played a role in the bearish movement of Zoetis stock.
• The lowered earnings forecast for USANA Health Sciences (USNA) and advised caution by analysts on its stock could have prompted a shift in investor sentiment towards other companies within the animal health sector, including Zoetis.

21.10.2025 - ZTS Stock was up 3.3%

• Recent fluctuations in the stock price over the last month and year have been overshadowed by today's positive movement of 0.38% to $117.53, hinting at a possible change in investor sentiment.
• The upward price trend could be linked to investors acknowledging Zoetis Inc.'s enduring value and growth opportunities within the animal health sector.
• Shareholders are displaying optimism regarding the company's future, fueling heightened buying activity and lifting the stock price.
• The surge in price relative to earnings signifies a reassessment of Zoetis Inc.'s worth by investors, positioning it as a potentially undervalued asset in the market.

21.10.2025 - ZTS Stock was up 5.2%

• Zoetis Inc. (ZTS) saw a significant bullish movement today, despite recent declines in stock price over the past month and year.
• Analysts are raising concerns about potential challenges in Zoetis' osteoarthritis pain franchise in a competitive market.
• The surge in Zoetis' stock price today may be linked to market optimism or positive developments within the company.
• Investors are keeping a close eye on Zoetis Inc.'s price over earnings ratio to assess if the stock is undervalued, potentially impacting today's bullish movement.

06.02.2026 - ZTS Stock was down 5.2%

• Zoetis Inc. (ZTS) witnessed a bearish market movement.
• The bearish trend could be linked to mixed results in the branded pharmaceutical sector, particularly highlighted in the Q4 earnings.
• While some companies like Bristol-Myers Squibb and Eli Lilly exceeded revenue expectations, the sector as a whole fell short of estimates, affecting investor sentiment.
• Moreover, a market report forecasting growth in the injected veterinary pain management drugs market may have raised concerns about potential competition for Zoetis Inc., influencing the negative market response.
• In conclusion, the underperformance of the sector combined with potential market challenges may have contributed to the bearish movement in Zoetis Inc. (ZTS) stock.

11.04.2026 - ZTS Stock was down 5.0%

• Zoetis Inc (ZTS) faced a significant decline in its U.S. companion animal business, leading to a reset of its full-year guidance. This was primarily due to increased price sensitivity, reduced vet visits, and competition from generic products.
• The market reacted negatively to the lowered guidance, resulting in a bearish movement for ZTS stock.
• Despite the challenges in the U.S. pet segment, Zoetis is focusing on integrated solutions, cost controls, and operational efficiency to address the issues and leverage its more resilient livestock and international businesses.
• The bearish movement in ZTS stock today can be attributed to the concerns surrounding the company's U.S. pet business and the strategic reset to tackle these challenges.

07.04.2026 - ZTS Stock was down 20.9%

• Zoetis (ZTS) stock might have experienced a bearish movement due to the broader market sentiment and company-specific factors.
• The negative market movement could be influenced by the news of other companies like Heron Therapeutics (HRTX) reporting a decline in earnings, potentially impacting investor confidence in the healthcare sector.
• Additionally, the focus on stocks hitting 52-week lows, including Zoetis, might have added to the bearish sentiment as investors reevaluate their positions based on fundamental company analysis.
• Overall, the combination of market dynamics, sector-specific news, and individual company performance could have contributed to Zoetis' bearish movement today.

07.04.2026 - ZTS Stock was down 22.5%

• Today's bearish movement in Zoetis (ZTS) stock can be attributed to a combination of factors:
• Analysts predicting a potential earnings beat for Zoetis' industry peer, Heron Therapeutics (HRTX), may have shifted investor focus away from Zoetis.
• Zoetis being mentioned with stocks hitting 52-week lows, despite its strong market position, could have raised concerns among investors about the company's short-term performance.
• Morningstar adjusting its long-term assumptions and valuation for Zoetis, although affirming its wide economic moat, might have prompted some investors to reassess their long-term investment thesis for the company.
• The general market sentiment towards the animal health industry, as indicated in Morningstar's analysis of Zoetis' market position and growth prospects, could have influenced the bearish movement in Zoetis stock today.

11.04.2026 - ZTS Stock was down 5.3%

• Zoetis Inc (ZTS) experienced a strong bearish movement following the company's decision to lower its full-year guidance due to challenges in its U.S. companion animal business.
• Increased price sensitivity, fewer vet visits, and generic competition in the U.S. pet segment have contributed to the decline in Zoetis' stock price.
• The company is implementing strategic measures focusing on integrated solutions, cost controls, and operational efficiency to address the challenges in its pet segment while leveraging its more resilient livestock and international businesses.
• Despite the bearish movement, Zoetis Inc's long-term prospects in the animal health industry remain solid, with potential for recovery as the company executes its strategic reset.